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| INTRODUCTION
The risk of venous thromboembolism (VTE) is increased in patients with cancer, by at least 4-to 7-fold. 1, 2 VTE significantly contributes to morbidity and a worse overall prognosis in patients with cancer. 3 VTE incidences ranging from 2% to 14% have been reported in different populations of patients with cancer, with the highest VTE risk identified in patients with pancreatic (~11%), lung (~8%), and stomach cancer (~8%). [1] [2] [3] [4] Patients with lung cancer have an elevated risk of VTE compared to other malignancies, with incidence rates ranging from 7% to 15%. [4] [5] [6] Various clinical predictors for increased VTE risk have been identified; however, further understanding of thrombogenic biomarkers is needed.
The pathophysiology of cancer-associated VTE involves complex interactions among the tumor (oncogenes and proteins), intracellular signaling pathways, coagulation system, and anticancer treatment. [7] [8] [9] A validated risk model for VTE has been developed based on data from a large, prospective US national cohort study of patients initiating a new chemotherapy regimen for solid tumors and lymphoma. 10 This risk model has been validated by independent investigators across a range of solid tumors [11] [12] [13] and has been incorporated into clinical guidelines for VTE risk assessment. [14] [15] [16] Although validated and utilized among a range of solid tumors, this risk model has not been consistent in stratifying lung cancer patients for VTE risk, 17, 18 especially in the era of targeted therapies and improved outcomes. Studies assessing epidermal growth factor receptor mutational status have demonstrated that positive status confers an almost 2-fold increased risk of VTE. 17 However, whether this association is related to the mutational status or the active intervention is unknown. Most recently, a global, prospective study (CANTARISK) showed that the risk model was not significantly associated with VTE in patients with non-small cell lung cancer. 19 Genomic predictors are widely used in oncology to inform prognosis and predict outcomes. [20] [21] [22] For example, Oncotype DX uses a 21-gene recurrence score to quantify distant recurrence risk and chemotherapy benefit in patients with breast cancer. 22 Although various clinical predictors of VTE risk have been identified, the identification of biomarkers, such as genomic predictors with higher sensitivity and specificity are needed to better discriminate patients at increased risk of VTE. Herein, we use an RNA sequencing strategy of lung cancers to nominate biomarkers of cancer-associated VTE.
| METHODS

| Identification of cohort and data collection
We evaluated patients with lung cancer from a prospective institutional review board-approved registry at the Cleveland Clinic with available tissue from surgical excision of a primary lung mass between 2010 and 2015. We propensity-matched patients on the basis of whether they developed VTE. VTE was defined as pulmonary embolism (PE), deep vein thrombosis (DVT), or catheter-associated thrombus from 3 months prior to diagnosis to 24 months after diagnosis. Nine patients with VTE were propensity-matched with 9 patients without VTE, with a score difference of <5%. Patients were matched based on the following criteria: age at cancer diagnosis, sex, race, history of prior cancer, date of lung cancer diagnosis, stage, histology (classified as adenocarcinoma, squamous cell carcinoma, mixed small cell cancer/large cell neuroendocrine, or neuroendocrine tumor), number of lines of chemotherapy, and length of follow-up. A logistic regression model including these variables was used to calculate the probability of VTE. This probability, or propensity score, was used to identify patients with VTE and without VTE with similar propensity scores, which resulted in the two groups being similar with respect to the matching characteristics.
Patients were staged surgically if treated with initial surgery, or otherwise staged clinically per the American Joint Committee on Cancer 7th edition. 23 RNA to proceed with sequencing analysis, due to tissue viability. were calculated using linear models in combination with moderated t statistic.
| Sample preparation for RNA sequencing
| RNA sequencing
| Single-sample GSEA and the information-based association metric
From 23 710 genes, a total of 1037 genes had differential gene expression. GSEA was performed on these differentially expressed genes. Association between GSEA profiles for each gene set and binary categorical variables were determined using an informationbased similarity metric (RNMI). This quantity is obtained by estimating the differential mutual information 24 between the VTE profile and each of the gene sets' GSEA profiles and then normalizing and rescaling it so that it is defined from 0 (no association) to 1 (perfect association). We estimate the differential mutual information using a kernel-based method 25 which places a Gaussian density centered at each data point and a width determined by a biased cross-validation estimate. 25, 26 The mutual information is then normalized 27 using the joint entropy to better account for the intrinsic differences in entropy associated with each single-sample GSEA profile. Nominal P values for the information-based association metric scores between the gene sets/pathways and response scores were estimated using an empirical permutation test.
| RESULTS AND DISCUSSION
The characteristics of the study population are presented in Table 1 . We identified 1037 genes with differential gene expression. In patients with VTE, 869 genes were overexpressed and 168 were underexpressed compared to patients without VTE (Figure 1 ). Of these, 276 genes with statistically significant (Q < 0.05) differential expression were identified, which were composed of 241 genes that were overexpressed in patients with lung cancer with VTE and 35 genes that were underexpressed. When gene expression was limited to those that included log (fold change) of +3 or greater and −3 or lower, a total of 146 genes were identified; 130 of which were overexpressed in patients with lung cancer with VTE and 16 genes that were underexpressed. We further limited genes to include a log (fold change) of +4 or greater and −3 or lower, and to include only those with Q < 0.05. This criterion established a total gene population of 27 genes, 15 of which were overexpressed in patients with lung cancer with VTE, and 12 genes that were underexpressed ( Table 2 ).
The most highly overexpressed genes were CECR1 and MIAT. CECR1 (4.9-fold elevation, Q = 0.000008) regulates cell proliferation and differentiation, while MIAT (4.8-fold elevation, Q = 0.000003) is linked to cardiac thrombosis. SHC4 (4.6, Q = 0.00003) is a gene that activates both Ras-dependent and Ras-independent pathways. We also identified genes involved in inflammatory pathways, which regulate the innate immune system, notably, NLRP14 GSEA showed gene sets associated with innate immunity and inflammatory pathways, which included IL2-STAT5 signaling, IL6-JAK-STAT3 signaling, interferon-response, complement, and inflammatory response (Table 3) . Conversely, genes associated with apoptosis pathways, myogenesis pathways, and epithelial mesenchymal pathways were underexpressed.
Several genes identified in our study are consistent with prior genes identified in arterial thrombosis and inflammatory response, for example, MIAT (myocardial infarction-associated transcript) and NLRP14 (nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 14). Recent studies have shown that MIAT is elevated and associated in patients with acute myocardial infarction (P < .001) in the peripheral blood and overexpressed in atherosclerotic plaques in patients undergoing coronary artery bypass surgery. [28] [29] [30] Additionally, serum levels of MIAT were positively associated with percentage of lymphocytes and negatively with neutrophils and platelet count, suggesting an inflammatory component. 29 Five patients with VTE and 3 patients without VTE had a history of CAD; MIAT was upregulated only in patients with VTE, suggesting that MIAT may be specific for VTE in our cohort, although confirmation is necessary.
Additionally, recent studies have identified gene expression profiles in patients with atherosclerosis that do not possess MIAT. 31, 32 Similarly, NLRP14 is a member of NLRP3 genes responsible for activation of the inflammasome complex, which may be associated with thrombotic events. 33, 34 These data are consistent with the knowledge that inflammatory states such as inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus are prothrombotic. [35] [36] [37] We identified several gene sets that implicated Kras signaling as associated with a higher risk of developing VTE. This finding is consistent with a study demonstrating metastatic colorectal patients (N = 172) with tumor mutant KRAS status (N = 65) were associated with a 14.5% increased risk of VTE. 38 A recent study identified differential gene expression in patients with colorectal cancer (CRC) with VTE only before CRC diagnosis and around the time (±3 months) of CRC diagnosis. 39 This study found 30 differentially expressed genes and performed Ingenuity pathway analysis on the top 10 genes in patients with VTE. This study also found inflammatory pathway associated with VTE and several shared genes with our study: SBSPON, DEFA5, PTPRR, SORBS1. Another study identified similar genes and pathways in patients with no cancer with single and recurrent VTE. Both cohorts had differential expression of immune and inflammatory pathways, specifically interferon-γ and STAT3, and cancer pathway RAS, which is consistent with our study. 40 Of the 36 genes presented in this study, overlap of inflammatory genes LTB and SLC7A11 were iden-
tified. An additional study identified 559 and 294 differentially TA B L E 2 Genes with differential expression in lung cancer patients with VTE genes overlapped between the two groups. 41 Leukocyte transendothelial migration and JAK-STAT3 signaling pathways were associated with recurrent VTE, the latter of which is consistent with our study.
In both patients with cancer and patients without cancer with VTE, inflammatory and immune pathways were identified across several studies, suggesting that these pathways are involved in thrombosis.
A limitation of this study is our sample size, which limited the power of this analysis. We were limited by tissue quality, as several tissue samples were of insufficient quality for RNA sequencing. In conclusion, to our knowledge, this study is the first to employ whole transcriptome RNA profiling strategy in lung cancer to identify differentially expressed genes and possible pathways that may guide therapeutic targets for cancer-associated VTE in the future.
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